Invasive management of acute coronary syndromes
نویسندگان
چکیده
منابع مشابه
Invasive management of the acute coronary syndromes
Acute coronary syndromes (ACS) represent a large segment of patients with coronary artery disease. This article discusses the algorithm of risk stratification in ACS and the evidence for selecting the invasive strategy in the management of ACS. Antiplatelet and antithrombotic therapy used in the management of ACS is also reviewed. Individualization of the dual antiplatelet therapy and of the an...
متن کاملEarly invasive versus selectively invasive management for acute coronary syndromes.
BACKGROUND Current guidelines recommend an early invasive strategy for patients who have acute coronary syndromes without ST-segment elevation and with an elevated cardiac troponin T level. However, randomized trials have not shown an overall reduction in mortality, and the reduction in the rate of myocardial infarction in previous trials has varied depending on the definition of myocardial inf...
متن کاملEarly Invasive versus Selectively Invasive Management for Acute Coronary Syndromes
From the Academisch Medisch Centrum, Amsterdam (R.J.W., F.W., G.T.S., J.G.P.T.); Medisch Centrum Alkmaar, Alkmaar (J.H.C.); Amphia Ziekenhuizen, Breda (P.H.J.M.D.); WestFriesGasthuis, Hoorn (C.L.J.); Elkerliek Ziekenhuis, Helmond (P.E.F.B.); Catharina Ziekenhuis, Eindhoven (H.R.M.); and Universitair Medisch Centrum St. Radboud, Nijmegen (F.W.A.V.) — all in the Netherlands. Address reprint reque...
متن کاملPrognostic value of C-Reactive Protein in Acute Coronary Syndromes
Introduction: Coronary artery disease (CAD) is among the most common, serious, chronic and life- threatening illnesses in the world. CAD represents a spectrum of conditions, with acute myocardial infarction at one end of it and silent ischemia at the other. There is growing evidence on importance of prognosis of C- reactive protein (CPR) in unstable angina and this protein is a maker of an adve...
متن کاملManagement of acute coronary syndromes with fondaparinux
Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use. It has been approved for the prevention of venous thromboembolism in patients undergoing orthopedic surgery and for the initial therapy of venous thromboembolism. In randomized clinical trials the value of fondaparinux in the treatment of ST-elevation myocardial infarctio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet
سال: 2016
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(16)31273-9